JP7734652B2 - 免疫複合体介在性腎臓障害の処置のための組み換えＩｇＧ Ｆｃ多量体 - Google Patents

免疫複合体介在性腎臓障害の処置のための組み換えＩｇＧ Ｆｃ多量体

Info

Publication number
JP7734652B2
JP7734652B2 JP2022516034A JP2022516034A JP7734652B2 JP 7734652 B2 JP7734652 B2 JP 7734652B2 JP 2022516034 A JP2022516034 A JP 2022516034A JP 2022516034 A JP2022516034 A JP 2022516034A JP 7734652 B2 JP7734652 B2 JP 7734652B2
Authority
JP
Japan
Prior art keywords
polypeptide
mutations
excluded
amino acid
multimer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022516034A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022547692A5 (https=
JP2022547692A (ja
Inventor
ヘレン・ヂィフィ・ツァオ
ロルフ・シュピリグ
アードリアン・チュルヒャー
アドリアーナ・バズ・モレリィ
Original Assignee
ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト filed Critical ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト
Publication of JP2022547692A publication Critical patent/JP2022547692A/ja
Publication of JP2022547692A5 publication Critical patent/JP2022547692A5/ja
Priority to JP2025084545A priority Critical patent/JP2025124714A/ja
Application granted granted Critical
Publication of JP7734652B2 publication Critical patent/JP7734652B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022516034A 2019-09-13 2020-09-11 免疫複合体介在性腎臓障害の処置のための組み換えＩｇＧ Ｆｃ多量体 Active JP7734652B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025084545A JP2025124714A (ja) 2019-09-13 2025-05-21 免疫複合体介在性腎臓障害の処置のための組み換えＩｇＧ Ｆｃ多量体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19197287.6 2019-09-13
EP19197287 2019-09-13
PCT/EP2020/075432 WO2021048330A1 (en) 2019-09-13 2020-09-11 Recombinant igg fc multimers for the treatment of immune complex-mediated kidney disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025084545A Division JP2025124714A (ja) 2019-09-13 2025-05-21 免疫複合体介在性腎臓障害の処置のための組み換えＩｇＧ Ｆｃ多量体

Publications (3)

Publication Number Publication Date
JP2022547692A JP2022547692A (ja) 2022-11-15
JP2022547692A5 JP2022547692A5 (https=) 2023-09-19
JP7734652B2 true JP7734652B2 (ja) 2025-09-05

Family

ID=68084577

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022516034A Active JP7734652B2 (ja) 2019-09-13 2020-09-11 免疫複合体介在性腎臓障害の処置のための組み換えＩｇＧ Ｆｃ多量体
JP2025084545A Pending JP2025124714A (ja) 2019-09-13 2025-05-21 免疫複合体介在性腎臓障害の処置のための組み換えＩｇＧ Ｆｃ多量体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025084545A Pending JP2025124714A (ja) 2019-09-13 2025-05-21 免疫複合体介在性腎臓障害の処置のための組み換えＩｇＧ Ｆｃ多量体

Country Status (9)

Country Link
US (1) US20220332847A1 (https=)
EP (1) EP4028415A1 (https=)
JP (2) JP7734652B2 (https=)
KR (1) KR20220062084A (https=)
CN (1) CN114401985A (https=)
AU (1) AU2020344164A1 (https=)
BR (1) BR112022003713A2 (https=)
CA (1) CA3150680A1 (https=)
WO (1) WO2021048330A1 (https=)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019511458A (ja) 2016-01-27 2019-04-25 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト 組み換えＩｇＧ Ｆｃ多量体
WO2019115745A1 (en) 2017-12-14 2019-06-20 CSL Behring Lengnau AG RECOMBINANT igG Fc MULTIMERS FOR THE TREATMENT OF NEUROMYELITIS OPTICA

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
GB9720054D0 (en) 1997-09-19 1997-11-19 Celltech Therapeutics Ltd Biological products
ES2551439T5 (es) 2003-07-01 2018-11-08 Ucb Biopharma Sprl Fragmentos Fab de anticuerpos modificados
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
AU2005285347A1 (en) * 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
PL2185589T3 (pl) 2007-06-01 2016-09-30 Środki wiążące receptor regionu stałego Fc immunoglobuliny
TWI542597B (zh) 2010-07-28 2016-07-21 吉林尼克公司 產生依序多聚體化免疫球蛋白ｆｃ組合物之天然人類蛋白質片段之融合蛋白
WO2013112986A1 (en) 2012-01-27 2013-08-01 Gliknik Inc. Fusion proteins comprising igg2 hinge domains
BR112015008663B1 (pt) 2012-10-17 2021-01-12 CSL Behring Lengnau AG Uso de uma quantidade eficaz de uma proteína polimérica compreendendo seis unidades demonômero de polipeptídeo
CA2939201A1 (en) 2014-03-05 2015-09-11 Ucb Biopharma Sprl Multimeric fc proteins
MX2016010951A (es) 2014-03-05 2016-11-29 Ucb Biopharma Sprl Proteinas de fc multimericas.
EP4299595A3 (en) 2014-05-02 2024-03-13 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc constructs
KR20250053203A (ko) 2015-07-24 2025-04-21 글리크닉 인코포레이티드 향상된 상보체 결합을 갖는 규칙적으로 다형체화된 면역글로불린 fc 조성물을 생성하기 위한 인간 단백질 단편의 융합 단백질
AU2017245143B2 (en) 2016-03-30 2024-01-11 Ab Biosciences, Inc. Recombinant intravenous immunoglobulin (rIVIG) compositions and methods for their production and use
DK3484514T3 (da) 2016-05-23 2024-01-29 Momenta Pharmaceuticals Inc Compositions and methods related to engineered fc constructs
AU2017279538A1 (en) 2016-06-07 2019-01-03 Gliknik Inc. Cysteine-optimized stradomers
JP7146771B2 (ja) 2017-01-06 2022-10-04 モメンタ ファーマシューティカルズ インコーポレイテッド 操作されたＦｃコンストラクトに関する組成物及び方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019511458A (ja) 2016-01-27 2019-04-25 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト 組み換えＩｇＧ Ｆｃ多量体
WO2019115745A1 (en) 2017-12-14 2019-06-20 CSL Behring Lengnau AG RECOMBINANT igG Fc MULTIMERS FOR THE TREATMENT OF NEUROMYELITIS OPTICA

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ADRIAN W ZUERCHER; ET AL，NEXT-GENERATION FC RECEPTOR-TARGETING BIOLOGICS FOR AUTOIMMUNE DISEASES，AUTOIMMUNITY REVIEWS，NL，ELSEVIER，2019年08月09日，VOL:18, NO:10，PAGE(S):1-9，https://doi.org/10.1016/j.autrev.2019.102366
BONNIE J B LEWIS; ET AL，USING THE K/BXN MOUSE MODEL OF ENDOGENOUS, CHRONIC, RHEUMATOID ARTHRITIS FOR THE 以下備考，BMC IMMUNOLOGY，2019年12月，VOL:20, NO:1，PAGE(S):1-10，https://doi.org/10.1186/s12865-019-0328-6，EVALUATION OF POTENTIAL IMMUNOGLOBULIN-BASED THERAPEUTIC AGENTS, INCLUDING IVIG AND 以下省略
LUKMANEE TRADTRANTIP; ET AL，RECOMBINANT IGG1 FC HEXAMERS BLOCK CYTOTOXICITY AND PATHOLOGICAL CHANGES IN 以下備考，NEUROPHARMACOLOGY，2018年02月08日，VOL:133，PAGE(S):345-353，https://doi.org/10.1016/j.neuropharm.2018.02.002，EXPERIMENTAL IN VITRO AND RAT MODELS OF NEUROMYELITIS OPTICA
MARIELLE A OTTEN; ET AL，BOTH COMPLEMENT AND IGG FC RECEPTORS ARE REQUIRED FOR DEVELOPMENT OF ATTENUATED 以下備考，THE JOURNAL OF IMMUNOLOGY，2009年09月15日，VOL:183, NO:6，PAGE(S):3980-3988，https://doi.org/10.4049/jimmunol.0901301，ANTIGLOMERULAR BASEMENT MEMBRANE NEPHRITIS IN MICE
ROLF SPIRIG; ET AL，RIGG1 FC HEXAMER INHIBITS ANTIBODY-MEDIATED AUTOIMMUNE DISEASE VIA EFFECTS ON 以下備考，THE JOURNAL OF IMMUNOLOGY，米国，THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS，2018年03月12日，VOL:200, NO:8，PAGE(S):2542-2553，https://doi.org/10.4049/jimmunol.1701171，COMPLEMENT AND FC[GAMMA]RS

Also Published As

Publication number Publication date
US20220332847A1 (en) 2022-10-20
CN114401985A (zh) 2022-04-26
WO2021048330A1 (en) 2021-03-18
AU2020344164A1 (en) 2022-04-14
JP2022547692A (ja) 2022-11-15
BR112022003713A2 (pt) 2022-08-09
CA3150680A1 (en) 2021-03-18
JP2025124714A (ja) 2025-08-26
KR20220062084A (ko) 2022-05-13
EP4028415A1 (en) 2022-07-20

Similar Documents

Publication Publication Date Title
US12071482B2 (en) Compositions and methods related to engineered Fc constructs
EP2927321B1 (en) Ch3 domain variant pair inducing formation of heterodimer of heavy chain constant region of antibody at high efficiency, method for preparing same, and use thereof
JP7045333B2 (ja) 操作されたＦｃコンストラクトに関する組成物及び方法
JP7097293B2 (ja) ヒトＦｃ受容体に結合する融合タンパク質
WO2022007807A1 (zh) 双特异性抗体及其应用
EP4242232A1 (en) Bispecific antibody and use thereof
WO2021238932A1 (zh) 多特异性抗体及其应用
WO2018032639A1 (zh) 活化的人凝血因子vii融合蛋白及其制备方法与用途
TW201706303A (zh) 具有高親和性、結合性及專一性之結合轉形生長因子－β１的ｓｃＦｖ－Ｆｃ二聚體
JP7734652B2 (ja) 免疫複合体介在性腎臓障害の処置のための組み換えＩｇＧ Ｆｃ多量体
US12122813B2 (en) Fusion protein comprising an antigen binding domain and a cytokine trimer domain
HK40105176A (en) Compositions and methods related to engineered fc constructs
HK40120543A (zh) 4-1bb结合蛋白
CN121712795A (zh) Fc区改造体
HK1228927A1 (en) Compositions and methods related to engineered fc constructs
HK1228927B (en) Compositions and methods related to engineered fc constructs

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230908

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230908

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241008

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241125

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250305

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250521

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250819

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250826

R150 Certificate of patent or registration of utility model

Ref document number: 7734652

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150